Skip to main content

849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

NCT04613596

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Mirati Therapeutics

The main purpose of this study is to evaluate the clinical activity of MRTX849 administered in combination with pembrolizumab in the first-line treatment setting to subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) with has a specific change in tumor genes (KRAS G12C mutation). This evaluation will include looking at how effective this study treatment is in decreasing the amount of cancer. Other objectives of the study include assessing what side effects occur and how often they occur, how quickly MRTX849 is absorbed into the blood stream, and how fast it is removed by the body. Several laboratory tests will be performed using samples of tumor tissue or blood to understand how and why the combination of study drugs may work.

This study is currently enrolling.